ATE80301T1 - Antibakterielle zusammensetzung zur oralen verabreichung. - Google Patents

Antibakterielle zusammensetzung zur oralen verabreichung.

Info

Publication number
ATE80301T1
ATE80301T1 AT89107040T AT89107040T ATE80301T1 AT E80301 T1 ATE80301 T1 AT E80301T1 AT 89107040 T AT89107040 T AT 89107040T AT 89107040 T AT89107040 T AT 89107040T AT E80301 T1 ATE80301 T1 AT E80301T1
Authority
AT
Austria
Prior art keywords
antibacterial composition
oral use
cyclodextrin
beta
substance
Prior art date
Application number
AT89107040T
Other languages
English (en)
Inventor
Toshihiro Kikkoji
Toshiyuki Kobayashi
Toyomi Sato
Koji Watanabe
Kenji Nishizawa
Original Assignee
Meiji Seika Kaisha
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Meiji Seika Kaisha filed Critical Meiji Seika Kaisha
Application granted granted Critical
Publication of ATE80301T1 publication Critical patent/ATE80301T1/de

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/54—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with at least one nitrogen and one sulfur as the ring hetero atoms, e.g. sulthiame
    • A61K31/542—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with at least one nitrogen and one sulfur as the ring hetero atoms, e.g. sulthiame ortho- or peri-condensed with heterocyclic ring systems
    • A61K31/545—Compounds containing 5-thia-1-azabicyclo [4.2.0] octane ring systems, i.e. compounds containing a ring system of the formula:, e.g. cephalosporins, cefaclor, or cephalexine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/70—Carbohydrates; Sugars; Derivatives thereof
    • A61K31/715—Polysaccharides, i.e. having more than five saccharide radicals attached to each other by glycosidic linkages; Derivatives thereof, e.g. ethers, esters
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/30—Macromolecular organic or inorganic compounds, e.g. inorganic polyphosphates
    • A61K47/36—Polysaccharides; Derivatives thereof, e.g. gums, starch, alginate, dextrin, hyaluronic acid, chitosan, inulin, agar or pectin
    • A61K47/40—Cyclodextrins; Derivatives thereof
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A61K9/2004—Excipients; Inactive ingredients
    • A61K9/2013—Organic compounds, e.g. phospholipids, fats
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A61K9/2004—Excipients; Inactive ingredients
    • A61K9/2022—Organic macromolecular compounds
    • A61K9/205—Polysaccharides, e.g. alginate, gums; Cyclodextrin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/04—Antibacterial agents
    • C—CHEMISTRY; METALLURGY
    • C08—ORGANIC MACROMOLECULAR COMPOUNDS; THEIR PREPARATION OR CHEMICAL WORKING-UP; COMPOSITIONS BASED THEREON
    • C08B—POLYSACCHARIDES; DERIVATIVES THEREOF
    • C08B37/00—Preparation of polysaccharides not provided for in groups C08B1/00 - C08B35/00; Derivatives thereof
    • C08B37/0006—Homoglycans, i.e. polysaccharides having a main chain consisting of one single sugar, e.g. colominic acid
    • C08B37/0009—Homoglycans, i.e. polysaccharides having a main chain consisting of one single sugar, e.g. colominic acid alpha-D-Glucans, e.g. polydextrose, alternan, glycogen; (alpha-1,4)(alpha-1,6)-D-Glucans; (alpha-1,3)(alpha-1,4)-D-Glucans, e.g. isolichenan or nigeran; (alpha-1,4)-D-Glucans; (alpha-1,3)-D-Glucans, e.g. pseudonigeran; Derivatives thereof
    • C08B37/0012—Cyclodextrin [CD], e.g. cycle with 6 units (alpha), with 7 units (beta) and with 8 units (gamma), large-ring cyclodextrin or cycloamylose with 9 units or more; Derivatives thereof
    • C08B37/0015—Inclusion compounds, i.e. host-guest compounds, e.g. polyrotaxanes

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Epidemiology (AREA)
  • Molecular Biology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Organic Chemistry (AREA)
  • Engineering & Computer Science (AREA)
  • Oncology (AREA)
  • Biochemistry (AREA)
  • Polymers & Plastics (AREA)
  • Biophysics (AREA)
  • Inorganic Chemistry (AREA)
  • Communicable Diseases (AREA)
  • Materials Engineering (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicinal Preparation (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Cephalosporin Compounds (AREA)
AT89107040T 1988-04-19 1989-04-19 Antibakterielle zusammensetzung zur oralen verabreichung. ATE80301T1 (de)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
JP63094543A JPH0678234B2 (ja) 1988-04-19 1988-04-19 経口投与用抗菌組成物
EP89107040A EP0339465B1 (de) 1988-04-19 1989-04-19 Antibakterielle Zusammensetzung zur oralen Verabreichung

Publications (1)

Publication Number Publication Date
ATE80301T1 true ATE80301T1 (de) 1992-09-15

Family

ID=14113229

Family Applications (1)

Application Number Title Priority Date Filing Date
AT89107040T ATE80301T1 (de) 1988-04-19 1989-04-19 Antibakterielle zusammensetzung zur oralen verabreichung.

Country Status (8)

Country Link
EP (1) EP0339465B1 (de)
JP (1) JPH0678234B2 (de)
KR (1) KR0139207B1 (de)
CN (1) CN1037063C (de)
AT (1) ATE80301T1 (de)
CA (1) CA1334934C (de)
DE (1) DE68902764T2 (de)
ES (1) ES2045239T3 (de)

Families Citing this family (10)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JPH0717866A (ja) * 1993-06-16 1995-01-20 Meiji Seika Kaisha Ltd 医薬組成物
JPH0840907A (ja) * 1994-08-03 1996-02-13 Meiji Seika Kaisha Ltd セファロスポリン注射剤
AR004014A1 (es) * 1995-10-13 1998-09-30 Meiji Seika Kaisha Una composicion antibacteriana de cefditoren pivoxilo para administracion oral y metodo para obtener dicha composicion
PL194097B1 (pl) * 1998-01-07 2007-04-30 Meiji Seika Kaisha Kompozycja zawierająca krystalograficznie trwałą amorficzną cefalosporynę i sposób jej wytwarzania
DE60334391D1 (de) 2002-10-02 2010-11-11 Meiji Seika Kaisha Antibakterielle medizinische zusammensetzung mit erhöhtem oralem absorptionsvermögen
JP2005162696A (ja) * 2003-12-04 2005-06-23 Nichiko Pharmaceutical Co Ltd 溶出性に優れたセフジトレンピボキシル製剤
JP2007106684A (ja) * 2005-10-11 2007-04-26 Sawai Pharmaceutical Co Ltd 抗菌性医薬組成物
CN101002782B (zh) * 2007-01-10 2010-05-19 南京师范大学 含有头孢呋辛酯环糊精包合物的药物组合物及其制备方法
CN101264085A (zh) * 2007-03-14 2008-09-17 南京师范大学 含有头孢地尼环糊精包合物的药物组合物及其制备方法
CN101264086A (zh) * 2007-03-14 2008-09-17 南京师范大学 含有头孢克肟环糊精包合物的药物组合物及其制备方法

Family Cites Families (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JPS60233012A (ja) 1984-05-02 1985-11-19 Takeda Chem Ind Ltd 経口用抗菌固型組成物
US4616008A (en) 1984-05-02 1986-10-07 Takeda Chemical Industries, Ltd. Antibacterial solid composition for oral administration
IE58487B1 (en) 1984-09-07 1993-09-22 Kaisha Maiji Seika New cephalosporin compounds and the production thereof
JPH08777B2 (ja) 1985-04-08 1996-01-10 武田薬品工業株式会社 経口用抗菌固型組成物

Also Published As

Publication number Publication date
DE68902764T2 (de) 1993-01-28
EP0339465A3 (en) 1990-03-28
KR0139207B1 (ko) 1998-05-15
ES2045239T3 (es) 1994-01-16
EP0339465A2 (de) 1989-11-02
CN1037063C (zh) 1998-01-21
CN1037652A (zh) 1989-12-06
JPH01268637A (ja) 1989-10-26
JPH0678234B2 (ja) 1994-10-05
CA1334934C (en) 1995-03-28
KR900015731A (ko) 1990-11-10
EP0339465B1 (de) 1992-09-09
DE68902764D1 (de) 1992-10-15

Similar Documents

Publication Publication Date Title
ATE80301T1 (de) Antibakterielle zusammensetzung zur oralen verabreichung.
NL970006I1 (nl) Gebruik van indolon-derivaten voor het bereiden van geneesmiddelen ter behandeling van de ziekte vanParkinson.
NZ212268A (en) Sustained release composition containing pyridyl-pyridinone derivatives and preparation thereof
AU8670891A (en) Pharmaceutical compositions active in the therapy of neurological affections in aids patients, containing as an active principle at least one compound selected from the group consisting of S-adenosyl-L-methionine salt, 5-methyl- tetrahydrofolic acid, 5-formyltetrahydrofolic acid
NZ237351A (en) Cephalosporin derivative, medicaments, intermediate compound
Sadaki et al. Studies on beta-lactam antibiotics for medicinal purpose. XVIII. Synthesis and structure-activity relationships of 7 beta-[(Z)-2-(2-aminothiazol-4-yl)-2-methoxyiminoacetamido]-3-substitut ed methyl-3-cephem-4-carboxylic acid derivatives
DE68916956D1 (de) Aktives mittel: lipid-komplex mit hohem verhältnis.
AU571506B2 (en) Cristalline ceftazidime
AU6839890A (en) Pharmaceutical preparation for oral administration in fluid form
EP0342423A3 (de) Heteroaroylhydrazid-Derivate von monocyclischen beta-Lactamantibiotika
Saikawa et al. Studies on beta-lactam antibiotics for medicinal purposes. XXII. Studies on the metabolism of pivaloyloxymethyl (6R, 7R)-7-[(Z)-2-(2-aminothiazol-4-yl)-2-methoxyiminoacetamido]-3-[(5-methyl-2H-tetrazol-2-yl) methyl]-3-cephem-4-carboxylate (T-2588)(2)
ATE144901T1 (de) Pharmazeutische kombinationspräparate enthaltend cefotaxim und xanthinderivate und deren verwendung
AU7411194A (en) Use of partially methylated beta-cyclodextrins as absorption promoters in the preparation of pharmaceutical compositions for the transcutaneous administration of active principles
AU560185B2 (en) Penicillin derivatives
Sorin et al. Pharmacokinetic and clinical study of cefuroxime in infants
Focht et al. In-vitro activity of cefuroxime. Efficacy against pathogenic agents of chronic bronchitis and chronic tonsillitis.
IL80558A0 (en) Cephalosporin derivatives and process for their preparation
Zhang The clinical study of cefamandole nafate.
NO884486L (no) Fremgangsmaate for fremstilling av cefalosporinderivater med forbedrede farmakokinetika.
Eichenwald Using the newer penicillins in pediatric practice.
Harvengt Drugs Recently Released In Belgium: Ceftazidime, Flecainide Acetate and Varicella Oka-Strain vaccine
JPS56140918A (en) Beta-lactam type antibiotic pharmaceutical preparation for rectum medication
HUT53654A (en) Process for producing cefemcarboxylic acid compounds and pharmaceutical compositions comprising such compounds
JO1229B1 (en) Penicillin derivatives
IT1238210B (it) Esteri del cefamandolo nafato, procedimento per la loro preparazione erelative composizioni farmaceutiche.

Legal Events

Date Code Title Description
UEP Publication of translation of european patent specification
EELA Cancelled due to lapse of time